Anthracycline-induced cardiomyopathy: The search continues

Kim, Agnes S.; Bergmann, Steven R.

doi:10.1007/s12350-015-0352-8

Cited by 3 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As anthracycline-induced cardiotoxicity is often progressive and irreversible 96 , it can increase mortality due to HF, despite the patient surviving cancer 97 . Though the exact mechanism of anthracycline-induced cardiotoxicity has yet to be determined, studies have shown that anthracyclines can impair intracellular Ca 2+ signalling and pro-survival signalling pathways as well as disrupt cardiac progenitor cells 98 . Furthermore, anthracyclines can accumulate in the mitochondria of cardiomyocytes, disrupting OXPHOS and leading to ROS formation, which can result in endomyocardial interstitial fibrosis and vacuolation 93 .…”

Section: Anthracycline Cardiomyopathymentioning

confidence: 99%

“…Furthermore, anthracyclines can accumulate in the mitochondria of cardiomyocytes, disrupting OXPHOS and leading to ROS formation, which can result in endomyocardial interstitial fibrosis and vacuolation 93 . Thus, it is widely believed that the generation of ROS, which results in increased apoptosis, disruption of mitochondrial structure and function in addition to energy depletion, plays a crucial role in the pathogenesis of anthracycline-induced cardiotoxicity 98 .…”

Section: Anthracycline Cardiomyopathymentioning

confidence: 99%

See 1 more Smart Citation

Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies

Ramachandra

Chua

Cong

et al. 2020

Cardiovascular Research

View full text Add to dashboard Cite

Normal cardiac contractile and relaxation functions are critically dependent on a continuous energy supply. Accordingly, metabolic perturbations and impaired mitochondrial bioenergetics with subsequent disruption of ATP production underpin a wide variety of cardiac diseases, including diabetic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, anthracycline cardiomyopathy, peripartum cardiomyopathy, and mitochondrial cardiomyopathies. Crucially, there are no specific treatments for preventing the onset or progression of these cardiomyopathies to heart failure, one of the leading causes of death and disability worldwide. Therefore, new treatments are needed to target the metabolic disturbances and impaired mitochondrial bioenergetics underlying these cardiomyopathies in order to improve health outcomes in these patients. However, investigation of the underlying mechanisms and the identification of novel therapeutic targets have been hampered by the lack of appropriate animal disease models. Furthermore, interspecies variation precludes the use of animal models for studying certain disorders, whereas patient-derived primary cell lines have limited lifespan and availability. Fortunately, the discovery of human-induced pluripotent stem cells has provided a promising tool for modelling cardiomyopathies via human heart tissue in a dish. In this review article, we highlight the use of patient-derived iPSCs for studying the pathogenesis underlying cardiomyopathies associated with metabolic perturbations and impaired mitochondrial bioenergetics, as the ability of iPSCs for self-renewal and differentiation makes them an ideal platform for investigating disease pathogenesis in a controlled in vitro environment. Continuing progress will help elucidate novel mechanistic pathways, and discover novel therapies for preventing the onset and progression of heart failure, thereby advancing a new era of personalized therapeutics for improving health outcomes in patients with cardiomyopathy.

show abstract

Section: Anthracycline Cardiomyopathymentioning

confidence: 99%

Section: Anthracycline Cardiomyopathymentioning

confidence: 99%

Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies

Ramachandra

Chua

Cong

et al. 2020

Cardiovascular Research

View full text Add to dashboard Cite

show abstract

“…It can be caused by chemotherapy and immunotherapy but rarely reported after RTX infusion. 8,9 We describe a case of a 56-year-old gentleman with chronic Epstein-Barr virus (EBV) infection who received rituximab infusion and developed isolated stress cardiomyopathy.…”

Section: Takotsubo Cardiomyopathy Secondary To Rituximabmentioning

confidence: 99%

“…Many cases of stress cardiomyopathy have been reported after 5-fluorouracil (5-FU), cetuximab, oxaliplatin, and capecitabine. 8,9 . However, an extensive review of the literature showed only 2 cases of RTX-induced stress cardiomyopathy reported to date.…”

Section: Takotsubo Cardiomyopathy Secondary To Rituximabmentioning

confidence: 99%

Takotsubo Cardiomyopathy Secondary to Rituximab

Gupta¹,

Sen²,

Khosla³

et al. 2020

American Journal of Therapeutics

View full text Add to dashboard Cite

Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2017. Part 1 of 2: Positron emission tomography, computed tomography, and magnetic resonance

AlJaroudi

Hage

2018

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

Several original articles and editorials have been published in the Journal of Nuclear Cardiology in 2017. It has become a tradition at the beginning of each year to summarize some of these key articles in 2 sister reviews. In this first part one, we will discuss some of the progress made in the field of heart failure (cardio-oncology, myocardial blood flow, viability, dyssynchrony, and risk stratification), inflammation, molecular and hybrid imaging using advancement in positron emission tomography, computed tomography, and magnetic resonance imaging.

show abstract

Anthracycline-induced cardiomyopathy: The search continues

Cited by 3 publications

References 28 publications

Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies

Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies

Takotsubo Cardiomyopathy Secondary to Rituximab

Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2017. Part 1 of 2: Positron emission tomography, computed tomography, and magnetic resonance

Contact Info

Product

Resources

About